Although it is true that the Nascent Biotech Inc (OTCMKTS:NBIO) stock was trading in a range on Wednesday, the company was actually in the news cycle and hence, it could be a good idea to perhaps take a look into it.
Trading Data
On Wednesday, NBIO stock ended flat at $0.14 with more than 528K shares traded, compared to its average volume of 217K shares. The stock moved within a range of $0.1300 – 0.1600 after opening trading at $0.14.
Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
The biotech company which is involved in the development of monoclonal antibodies announced yesterday that its Chief Executive Officer Sean Carrick had been the subject of an interview with Proactive Investors recently. It was a significant announcement since CEO interviews can often work as a trigger for potential investors and can lead to a boost in the near to medium term.
At the interview, Carrick provided a summary of the history of Nascent Biotech and also provided key insights into the current situation at the company. More importantly, he had also spoken extensively about the progress that had been made by Nascent in hitting its milestones.
During the course of the interview, Carrick had stated that Nascent was moving forward with the Phase 1 clinical trial on an expected time frame. He went on to add that the project could eventually lead to unlocking of considerable value for the shareholders.
Key Quote
Mr. Carrick stated, “The Company is moving forward as expected with our Phase I Clinical Trial. In the process, we are learning a lot about PTB. We believe that, as we progress forward with the phase I Clinical Trial and move into phase II, achievement of our milestones will drive significant value for the Company and our shareholders.”
Technical Data
NBIO stock is below the 20-Day and 50-Day Moving averages of $0.12 and $0.08 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.08.
